Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper (SAPHYR Trial)

home / between-the-lines / sarilumab-for-relapse-of-polymyalgia-rheumatica-during-glucocorticoid-taper-saphyr-trial

The SAPHYR trial unveils serilumab's potential as a steroid-sparing option for refractory Polymyalgia Rheumatica, positively impacting patients, providers, and payers. Robert Spiera, MD, and Dana McCormick, RPh, discuss how Serilumab could reduce steroid-related side effects in these patients.

© 2024 MJH Life Sciences

All rights reserved.